Genotypic tropism testing in proviral DNA to guide maraviroc initiation in aviremic subjects: 48-week analysis of the PROTEST study.
Por:
Garcia F, Poveda E, Pérez-Elías MJ, Quero JH, Ribas MA, Martínez-Madrid OJ, Flores J, Crespo M, Gutiérrez F, García-Deltoro M, Imaz A, Ocampo A, Artero A, Blanco F, Bernal E, Pasquau J, Mínguez-Gallego C, Pérez N, Aiestarán A and Paredes R
Publicada:
2 nov 2014
Resumen:
In a previous interim 24-week virological safety analysis of the PROTEST study (1), initiation of Maraviroc (MVC) plus 2 nucleoside reverse-transcriptase inhibitors (NRTIs) in aviremic subjects based on genotypic tropism testing of proviral HIV-1 DNA was associated with low rates of virological failure. Here we present the final 48-week analysis of the study.
Filiaciones:
Garcia F:
Hospital Universitario San Cecilio, Granada, Spain
Poveda E:
INIBIC-Complexo Hospitalario Universitario de A Coruña, A Coruña, Spain
Pérez-Elías MJ:
Hospital Ramón y Cajal, Madrid, Spain
Quero JH:
Hospital Universitario San Cecilio, Granada, Spain
Ribas MA:
Hospital Son Espases, Palma de Mallorca, Spain
Martínez-Madrid OJ:
Hospital General Universitario Santa Lucía, Cartagena, Spain
:
Hospital Arnau de Vilanova, Valencia, Spain
Crespo M:
Hospital Universitari Vall d'Hebron, Barcelona, Spain
:
Hospital Universitario de Elche, Elche, Spain
García-Deltoro M:
Hospital General Universitario de Valencia, Valencia, Spain
Imaz A:
Hospital de Bellvitge, Barcelona, Spain
Ocampo A:
Hospital Xeral de Vigo, Vigo, Spain
:
Hospital Universitario Dr. Peset, Valencia, Spain
Blanco F:
Hospital Carlos III, Madrid, Spain
Bernal E:
Hospital Reina Sofía, Murcia, Spain
Pasquau J:
Hospital Virgen de la Nieves, Granada, Spain
:
Hospital General de Castelló, Castelló, Spain
Pérez N:
Hospital Universitari Germans Trias i Pujol, Badalona, Spain
Aiestarán A:
Hospital Universitari Vall d'Hebron, Barcelona, Spain
Paredes R:
IrsiCaixa AIDS Research Institute, Badalona, Spain
|